关于WSi12超原子作为药物载体的潜力:一个DFT研究

Bin Liu1, Jia-Chen Zhang1,2, Ya-Ling Ye1,3

  • 1Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, The School of Pharmacy, Fujian Medical University, Fuzhou 350108, People's Republic of China. sunwm@fjmu.edu.cn.

概括

烯化 (WSi12) 超原子显示了作为5-氨酸 (5-ASA),异化 (INH) 和6-硫 (6-TG) 的药物载体的潜力. 然而,WSi12不适合用于5-甲 (5-Fu) 和temozolomide (TMZ) 的输送.